Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. - Université de Lorraine Access content directly
Journal Articles Current Drug Targets Year : 2013

Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.

Abstract

The advent of anti-Tumor Necrosis Factor (TNF) therapy has changed the way of treating inflammatory bowel disease (IBD). However, primary and secondary failure are relatively frequent with all anti-TNF agents, which are available only as parenteral agents. Tofacitinib is an oral janus kinase (JAK) inhibitor that inhibits JAK family kinase members, in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors. It first proved its efficacy as an immunosuppressive regimen after renal transplantation, and was recently approved by the FDA for rheumatoid arthritis. First data in IBD are promising, especially in ulcerative colitis. Ongoing clinical trials in both UC and Crohn's disease (CD) are needed to further explore its efficacy in CD and to better assess its safety profile.
No file

Dates and versions

hal-01702865 , version 1 (07-02-2018)

Identifiers

  • HAL Id : hal-01702865 , version 1
  • PUBMED : 23627915

Cite

Lucine Vuitton, Stéphane Koch, Laurent Peyrin-Biroulet. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.. Current Drug Targets, 2013, pp.1385-91. ⟨hal-01702865⟩
23 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More